Pharmacokinetics of tilmicosin in chicken joints based on a novel microdialysis sampling method

Zhang, Nan; Yan, Xiu; Liu, Jinxin; Songyang, Zhou; Zhou, Minghu; Song, Shuti; Yao, Zhaofeng; Jia, Yixin; Yuan, Shuofeng

doi:10.1111/jvp.13118

Cited by 3 publications

(1 citation statement)

References 28 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, tilmicosin is a very promising drug for the treatment of respiratory disorders in donkeys. The pharmacokinetics of tilmicosin have been studied in horse [13], swine [19], cattle [20], sheep [8], chicken [21,22], and rabbit [23], and data in donkeys are still vacant. Therefore, the present study was carried out around the pharmacokinetics of tilmicosin in plasma, urine, and feces of donkeys in order to determine the suitability of tilmicosin for donkeys.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Tilmicosin in Plasma, Urine and Feces after a Single Intragastric Administration in Donkey (Equus asinus)

Yang,

Liu,

Guo

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Tilmicosin, a macrolide antibiotic, has the potential to treat bacterial respiratory infections in donkeys. However, the pharmacokinetics of tilmicosin in donkeys have not been reported. Objectives: The aim of this study was to investigate the pharmacokinetics of tilmicosin in donkey plasma, urine and feces after a single intragastric administration to determine the suitability of tilmicosin for donkeys. Animals: A total of 4 healthy fattening male donkeys were selected with body weights of 148, 140, 145, and 135 kg, with an average body weight of 142.00 ± 4.95 kg. Methods: The donkeys were administered intragastrically a single dose of 10 mg·kg-1 BW tilmicosin. Blood, urine and fecal samples were collected. The concentrations of tilmicosin in plasma, urine, and feces were determined using high-performance liquid chromatography-tandem masss pectrometry. Results: After a single intragastric administration of 10 mg·kg-1 body weight, tilmicosin in donkey plasma reached a maximum concentration of 11.23 ± 5.97 mg·L-1 at 0.81 ± 0.11 h, with a mean residence time of 8.05 ± 2.44 h, a Cl/F of 0.48±0.22 L·kg-1·h-1, and a Vd/F of 9.28 ± 4.10 L·kg-1. The percentage of tilmicosin excreted through the urine of donkeys is (2.47±0.43)%, and the percentage excreted through the feces is (66.43±8.65)%. Conclusions: A single intragastric administration of 10 mg·kg-1 BW of tilmicosin to donkeys was rapidly absorbed and was able to achieve plasma concentrations of against pathogenic bacteria.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Tilmicosin in Plasma, Urine and Feces after a Single Intragastric Administration in Donkey (Equus asinus)

Yang,

Liu,

Guo

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Pharmacokinetics of tilmicosin in plasma, urine and feces after a single intragastric administration in donkey (Equus asinus)

Yang,

Liu,

Guo

et al. 2024

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Tilmicosin, a macrolide antibiotic, has the potential to treat bacterial infections in donkeys. However, the pharmacokinetics of tilmicosin in donkeys have not been reported. The aim of this study was to investigate the pharmacokinetics of tilmicosin in donkey plasma, urine, and feces after a single intragastric administration to determine the suitability of tilmicosin for donkeys. A total of 5 healthy male donkeys with similar body weights were selected. The donkeys were administered a single dose of 10 mg · kg−1 body weight (BW) tilmicosin by gavage. The concentrations of tilmicosin in plasma, urine, and feces were determined. The results showed that after a single intragastric administration of 10 mg · kg−1 body weight, tilmicosin in donkey plasma reached a maximum concentration of 11.23 ± 5.37 mg · L−1 at 0.80 ± 0.10 h, with a half‐life of 14.49 ± 7.13 h, a mean residence time of 28.05 ± 3.05 h, a Cl/F of 0.48 ± 0.18 L · kg−1 · h−1, and a Vd/F of 9.28 ± 2.63 Lkg−1. The percentage of tilmicosin excreted through the urine of donkeys is 2.47%, and the percentage excreted through the feces is 66.43%. Our study provides data to inform the use of tilmicosin in donkeys.

show abstract

The pharmacokinetics/pharmacodynamics integration of tilmicosin against Mycoplasma synoviae in vitro and in vivo

Yan,

Liu,

et al. 2024

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Mycoplasma synoviae (MS) infection is a serious threat to poultry industry in China. Tilmicosin is a semisynthetic macrolide antibiotic used only in animals and has shown potential efficacy against MS, but there were no reported articles concerning the pharmacokinetics/pharmacodynamics (PK/PD) interactions of tilmicosin against MS in vitro and vivo. This study aimed to assess the antibacterial activity of tilmicosin against MS in vitro and in vivo using PK/PD model to provide maximal efficacy. The minimum inhibitory concentration (MIC) and killing rates of different drug concentrations were measured using the microdilution method in vitro. Then, tilmicosin was administered orally to the MS‐infected chickens at doses of 7.5 and 60 mg/kg, and the PK parameters of tilmicosin in joint dialysates were determined using high‐pressure liquid chromatography/tandem mass spectrometry (HPLC‐MS/MS) combined with the microdialysis technique. The antibacterial effect (△E) was calculated when the infected chickens were administered a single oral dose of tilmicosin at 4, 7.5, 15, 30, and 60 mg/kg b.w. The PK and PD data were fitted using the Sigmoid Emax model to evaluate the PK/PD interactions of tilmicosin against MS. The bactericidal activity of tilmicosin against MS was concentration dependent. Furthermore, the PK/PD index of AUC0–72h/MIC exhibited the most optimal fitting results (R2 = .98). The MS load decreased by 1, 2, and 3 Log10 CFU/mL, then AUC/MIC was determined as 13.99, 20.53, and 28.23 h, respectively, and the bactericidal effect can be achieved when the dose of MS‐infected chickens is at 31.64 mg/kg b.w. The findings of this study hold significant implications for optimizing the treatment regimen for MS infection.

show abstract

Pharmacokinetics of tilmicosin in chicken joints based on a novel microdialysis sampling method

Cited by 3 publications

References 28 publications

Pharmacokinetics of Tilmicosin in Plasma, Urine and Feces after a Single Intragastric Administration in Donkey (Equus asinus)

Pharmacokinetics of Tilmicosin in Plasma, Urine and Feces after a Single Intragastric Administration in Donkey (Equus asinus)

Pharmacokinetics of tilmicosin in plasma, urine and feces after a single intragastric administration in donkey (Equus asinus)

The pharmacokinetics/pharmacodynamics integration of tilmicosin against Mycoplasma synoviae in vitro and in vivo

Contact Info

Product

Resources

About